
Eli Lilly and Company, Johnson & Johnson, and Merck & Co., Inc. are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell medicines and other drug-related products. For stock market investors, these stocks represent ownership in the pharmaceutical industry and may offer growth potential from successful drug approvals and sales, but they can also carry risks related to clinical trials, regulatory decisions, patent expirations, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read Our Latest Research Report on JNJ
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read Our Latest Research Report on MRK
See Also
- MarketBeat’s Top Five Stocks to Own in August 2026
- Photronics Is Quietly Becoming a Key Winner From the AI Boom
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
- OpenAI’s Jalapeño Chip Could Change the AI Hardware Race
- Gold and Bitcoin Are Rebounding—2 ETFs Give Investors a Different Kind of Exposure
